Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-15T17:13:17.595Z Has data issue: false hasContentIssue false
  • English
  • Français

Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway

Published online by Cambridge University Press:  21 February 2013

Thomas R. Einarson ,
Colin Vicente ,
Roman Zilbershtein ,
Charles Piwko ,
Christel N. Bø ,
Hanna Pudas  and
Michiel E. H. Hemels
Thomas R. Einarson*
Affiliation:
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
Colin Vicente
Affiliation:
Pivina Consulting Inc., Mississauga, ON, Canada
Roman Zilbershtein
Affiliation:
Pivina Consulting Inc., Mississauga, ON, Canada
Charles Piwko
Affiliation:
Pivina Consulting Inc., Mississauga, ON, Canada
Christel N. Bø
Affiliation:
Janssen, Oslo, Norway
Hanna Pudas
Affiliation:
Janssen, Espoo, Finland
Michiel E. H. Hemels
Affiliation:
Janssen, Birkerød, Denmark
*
Thomas R. Einarson, PhD, Leslie Dan Faculty of Pharmacy, Toronto, ON M5V 3 M8 Canada. Tel: +416‐978‐6212; Fax: +416‐978‐1833; E‐mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Paliperidone palmitate long‐acting injection (PP‐LAI) has recently been approved for treatment of chronic schizophrenia. Its cost‐effectiveness has not been established. The objective was to compare direct costs and outcomes between PP‐LAI and olanzapine pamoate (OLZ‐LAI) in treating chronic schizophrenia in Norway from the perspective of the government payer.

Methods

We used a decision analytic model over a 1‐year time horizon. Clinical inputs were derived from the literature and an expert panel; costs were taken from standard lists, adjusted to 2010 Norwegian kroner (NOK). Discounting was not done. Main outcomes included average cost per patient treated, hospitalisations, emergency room (ER) visits and quality‐adjusted life years (QALYs). The pharmacoeconomic outcome was the incremental cost per QALY. Robustness was examined using one‐way sensitivity analyses on critical variables and a 5000‐iteration probabilistic Monte Carlo sensitivity analysis with all variables included.

Results

PP‐LAI generated 0.845 QALY at a cost of 151 336 NOK of which 23% was due to drugs; 25% of patients were hospitalised and another 12% required ER visits. OLZ‐LAI cost 174 351 NOK (21% due to drugs); patient outcomes included 0.844 QALY, 27% hospitalisations and 14% ER visits. PP‐LAI dominated OLZ‐LAI in the base case. The analysis was reasonably robust against variations in drug cost but sensitive to small changes in adherence and hospitalisation rates. Overall, PP‐LAI was dominant over OLZ‐LAI in 54.5% of simulations. Replacing OLZ‐LAI with PP‐LAI would be cost saving for the Norwegian healthcare system.

Conclusion

PP‐LAI was cost‐effective compared with OLZ‐LAI in treating patients with chronic schizophrenia in Norway but sensitive to changes in adherence and hospitalisation rates.

Keywords

Norwayolanzapine pamoatepaliperidone palmitatepharmacoeconomic analysisschizophrenia
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 25 , Issue 2 , April 2013 , pp. 85 - 94
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Karagianis, J, Novick, D, Pecanek, J et al. Worldwide‐Schizophrenia Outpatient Health Outcomes (W‐SOHO): baseline characteristics of pan‐regional observational data from more than 17,000 patients. Int J Clin Pract 2009;63:1578–1588.Google Scholar
2Möller, H‐J. Long‐acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007;67:1541–1566.CrossRefGoogle ScholarPubMed
3Kane, J, Eerdekens, M, Lindenmayer, J‐P, Keith, S, Lesem, M, Karcher, K. Long‐acting injectable risperidone: efficacy and safety of the first long‐acting atypical antipsychotic. Am J Psychiatry 2003;160:1125–1132.CrossRefGoogle ScholarPubMed
4Nasrallah, H. The case for long‐acting antipsychotic agents in the post‐CATIE era. Acta Psychiatr Scand 2007;115:260–267.Google Scholar
5Nielsen, J, Le Quach, P, Emborg, C et al. 10‐Year trends in the treatment and outcomes of patients with first‐episode schizophrenia. Acta Psychiatr Scand 2010;122:356–366.Google Scholar
6European Medicines Agency. Risperdal Consta® summary of product characteristics. URL http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Risperdal_Consta_30/WC500008170.pdf [accessed on 8 August 2011].Google Scholar
7European Medicines Agency. Assessment report for Zypadhera. Doc. Ref EMEA/608654/2008. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000890/WC500054428.pd. Procedure No. EMEA/H/C/000890, 1–63. 2008 [accessed on 8 August 2011].Google Scholar
8European Medicines Agency. Xeplion® opinion. URL http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002105/smops/Positive/human_smop_000162.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d127 [accessed on 8 August 2011].Google Scholar
9Detke, H, Mcdonnell, D, Brunner, E et al. Post‐injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long‐acting injection, I: analysis of cases. BMC Psychiatry 2010;10:32.Google Scholar
10Alphs, L, Gopal, S, Karcher, K et al. Are long‐acting intramuscular formulations of risperidone or paliperidone palmitate associated with post‐injection delirium sedation syndrome? An assessment of safety databases. Curr Drug Saf 2011;6:43–45.Google Scholar
11Furiak, N, Ascher‐Svanum, H, Klein, R et al. Cost‐effectiveness of olanzapine long‐acting injection in the treatment of patients with schizophrenia in the United States: a micro‐simulation economic decision model. Curr Med Res Opin 2011;27:713–740.Google Scholar
12Glazer, W, Ereshefsky, L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996;57:337–345.Google Scholar
13European Medicines Agency. Xeplion® summary of product characteristics. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf [accessed on 8 August 2011].Google Scholar
14European Medicines Agency. Zypadhera® summary of product characteristics. URL http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/000890/WC500054429.pdf. 20‐4‐2010 [accessed on 8 August 2011].Google Scholar
15Gopal, S, Vijapurkar, U, Lim, P, Morozova, M, Eerdekens, M, Hough, D. A 52‐week open‐label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010;25:685–697.Google Scholar
16Fleischhacker, WW, Gopal, S, Lane, L et al. A randomized trial of paliperidone palmitate and risperidone long‐acting injectable in schizophrenia. Int J Neuropsychopharmacol 2011;22:1–12. DOI: 10.1017/S1461145711001076.Google Scholar
17Kane, J, Detke, H, Naber, D et al. Olanzapine long‐acting injection: a 24‐week, randomized, double‐blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010;167:181–189.Google Scholar
18Gopal, S, Hough, D, Xu, H et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double‐blind, placebo‐controlled, dose–response study. Int Clin Psychopharmacol 2010;25:247–256.Google Scholar
19Pandina, GJ, Lane, R, Gopal, S et al. A double‐blind study of paliperidone palmitate and risperidone long‐acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:218–226.Google Scholar
20Hough, D, Lindenmayer, J‐P, Gopal, S et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:1022–1031.Google Scholar
21Nasrallah, HA, Gopal, S, Gassmann‐Mayer, C et al. A controlled, evidence‐based trial of paliperidone palmitate, a long‐acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010;35:2072–2082.Google Scholar
22Pandina, GJ, Lindenmayer, J‐P, Lull, JM et al. A randomized, placebo‐controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychiatry 2010;30:235–244.Google Scholar
23Lauriello, J, Lambert, T, Andersen, S, Lin, D, Taylor, C, Mcdonnell, D. An 8‐week, double‐blind, randomized, placebo controlled study of olanzapine long‐acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69:790–799.Google Scholar
24Hough, D, Gopal, S, Vijapurkar, U, Lim, P, Morozova, M, Eerdekens, M. Paliperidone palmitate maintenance treatment in delaying the time‐to‐relapse in patients with schizophrenia: a randomized, double‐blind, placebo‐controlled study. Schiz Res 2010;116:107–117.Google Scholar
25Morken, G, Widen, J, Grawe, R. Non‐adherence to antipsychotic medication, relapse and rehospitalisation in recent‐onset schizophrenia. BMC Psychiatry 2008;8:1–8.Google Scholar
26Simonsen, E, Friis, S, Opjordsmoen, S et al. Early identification of non‐remission in first‐episode psychosis in a two‐year outcome study. Acta Psychiatr Scand 2010;122:375–383.Google Scholar
27Kane, J, Honigfeld, G, Singer, J et al. Clozapine for the treatment‐resistant schizophrenic: a double‐blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–796.CrossRefGoogle ScholarPubMed
28Leponex product monograph. Oslo: Novartis Norge AS, 5 May 2010.Google Scholar
29Wahlbeck, K, Cheine, M, Essali, A, Adams, C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta‐analysis of randomized trials. Am J Psychiatry 1999;156:990–999.Google Scholar
30Olivares, J, Peuskens, J, Pecanek, J et al. Clinical and resource‐use outcomes of risperidone long‐acting injection in recent and long‐term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197–2206.Google Scholar
31Mehnert, A, Diels, J. Impact of administration interval on treatment retention with long‐acting antipsychotics in schizophrenia. Presented at the Tenth Workshop on Costs and Assessment in Psychiatry – Mental Health Policy and Economics; 25–27 March 2011, Venice, Italy. 2011.Google Scholar
32Ascher‐Svanum, H, Faries, D, Zhu, B et al. Medication adherence and long‐term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453–460.Google Scholar
33Weiden, P, Kozma, C, Grogg, A et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886–891.Google Scholar
34Nicholl, D, Akhras, K, Diels, J et al. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective. Curr Med Res Opin 2010;26:943–955.Google Scholar
35Norwegian Medicines Agency. Database – approved and marketed pharmaceuticals. URL http://www.legemiddelverket.no/custom/Preparatsok/prepSearch_80333.aspx [accessed on 26 November 2011].Google Scholar
36Norwegian Health Directorate. Samdata specialisthelsetjenesten 2009. URL http://www.helsedirektoratet.no/vp/multimedia/archive/00300/Samdata_spesialisth_300999a.pdf. Norwegian Health Directorate [accessed on 6 June 2011].Google Scholar
37European Central Bank. Statistical data warehouse. URL http://sdw.ecb.europa.eu/quickview.do?SERIES_KEY=120.EXR.A.NOK.EUR.SP00.A [accessed on 6 June 2011].Google Scholar
38Statistics Norway. Consumer price index. http://statbank.ssb.no/statistikkbanken/Default_FR.asp?PXSid=0&nvl=true&PLanguage=0&tilside=selecttable/hovedtabellHjem.asp&KortnavnWeb=kpi. Statistics Norway [accessed on 6 June 2011].Google Scholar
39Berg, J, Restan, A. Duration of bed occupancy as calculated at a random chosen day in an acute care ward. Implications for the use of scarce resources in psychiatric care. Arch Gen Psychiatry 2005;4:1–6.Google Scholar
40McCracken, C, Dalgard, O, Ayuso‐Mateos, J et al. Health service use by adults with depression: community survey in five European countries Evidence from the ODIN study. Br J Psychiatry 2006;181:161–167.CrossRefGoogle Scholar
41Svendsen, B, Myhr, K, Nyland, H et al. The cost of multiple sclerosis in Norway – (and how certain can we be?). Bergen: Institutt for foretaksøkonomi, Department of Finance and Management Science, 2006.Google Scholar
42Briggs, A, Wild, D, Lees, M et al. Impact of schizophrenia and schizophrenia treatment‐related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008;6:105.CrossRefGoogle ScholarPubMed
43Cummins, C, Stevens, A, Kisely, S. The use of olanzapine as a first and second choice treatment in schizophrenia. Birmigham, UK: Department of Public Health & Epidemiology, University of Birmingham. A West Midlands Development and Evaluation Committee Report, 1998.Google Scholar
44Lenert, L, Sturley, A, Rapaport, M et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schiz Res 2004;71:155–165.CrossRefGoogle Scholar
45Oh, P, Lanctôt, K, Mittmann, N et al. Cost‐utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001;4:137–156.Google Scholar
46Revicki, D, Shakespeare, A, Kind, P. Preferences for schizophrenia‐related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996;11:101–108.Google Scholar
47Statistics Norway. URL http://www.ssb.no/en/ [accessed on 5 December 2011].Google Scholar
48Faerden, AA, Waal, HH, Rønnow, SS. Long‐term psychiatric patients in a sector of Oslo. Tidsskr Nor Laegeforen 1995;115:3638–3641.Google Scholar
49National Institute for Health and Clinical Excellence (NICE). URL http://www.nice.org.uk/ [accessed on 5 December 2011].Google Scholar
50Yahoo Finance currency converter. http://ca.finance.yahoo.com/currencies/converter/#from=GBP;to=EUR;amt=1 [accessed on 4 December 2011].Google Scholar
51Pandina, GJ, Lane, R, Gopal, S et al. A randomized, double‐blind, comparative study of flexible doses of paliperidone palmitate and risperidone long‐acting therapy in patients with schizophrenia. Presented at the American College of Neuropsychopharmacology 48th Annual Meeting, Hollywood, FL, 6–10 December 2009.Google Scholar
52Einarson, T, Hemels, M, Nuamah, I et al. Hyperprolactinemia with paliperidone palmitate: analysis of adverse events and abnormal laboratory values in randomized clinical trials. Ann Pharmacother 2012;46 (In submission).Google Scholar
53All Wales Medicines Strategy Group. Final appraisal report: Olanzapine depot (ZypAdhera®), Lilly UK. Advice No: 1510 – October 2010. URL http://www.wales.nhs.uk/sites3/Documents/371/olanzapine%20depot%20(ZypAdhera)%20schizophrenia.pdf [accessed on 8 August 2011].Google Scholar
54Farahati, F, Boucher, M, Moulton, K et al. Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment [Technology report number 91]. Ottawa: Canadian Agency for Drugs and Technologies in Heath, 2007.Google Scholar
55Tenback, DE, van Harten, PN, Slooff, CJ, van Os, J. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol 2010;24:1031–1035.CrossRefGoogle ScholarPubMed
56Honkonen, T, Henriksson, M, Koivisto, AM, Stengård, E, Salokangas, RK. Violent victimization in schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2004;39:606–612.Google Scholar
57Laajasalo, T, Hakkanen, H. Excessive violence and psychotic symptomatology among homicide offenders with schizophrenia. Crim Behav Ment Health 2006;16:242–253.Google Scholar
58Boye, B, Bentsen, H, Ulstein, I et al. Relatives' distress and patients' symptoms and behaviours: a prospective study of patients with schizophrenia and their relatives. Acta Psychiatr Scand 2001;104:42–50.CrossRefGoogle ScholarPubMed